Muhammad Husnain

Interests

No activities entered.

Courses

No activities entered.

Scholarly Contributions

Chapters

• Husnain, M., Zhang, Y., & Rosenblatt, J. (2021). The Role of Breg Cells in Modulating the Antitumor Immune Response. In Cancer Immunotherapy Principles and Practice, Second Edition. New York: NY: Demos Medical Publishing.

Journals/Publications

• Asghar, K., Zafar, M., Holland, E., Abduljabbar, A. B., Albagoush, S. A., Asghar, N., Sood, A., Dufani, J. M., Thirumalaredy, J., DeVrieze, B., Tauseef, A., & Husnain, M. (2024). A systematic review and meta-analysis on utilizing anti-CD19 chimeric antigen receptor T-cell therapy as a second-line treatment for relapsed and refractory diffuse large B-cell lymphoma. Frontiers in oncology, 14, 1407001.
  More info

  Inconsistent results observed in recent phase III trials assessing chimeric antigenic receptor T (CAR-T) cell therapy as a second-line treatment compared to standard of care (SOC) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) prompted a meta-analysis to assess the effectiveness of CAR-T cell therapy in this setting.
• Cracchiolo, M. J., Davis, L., Matiatos, A. P., Davini, D. W., Husnain, M., Simpson, R. J., Voudouris, V., & Katsanis, E. (2024). Comparable Efficacy of Oral Bendamustine versus Intravenous Administration in Treating Hematologic Malignancies. Research square.
  More info

  The purpose of this study was to analyze potential differences in antitumor efficacy and pharmacokinetics between intravenous (IV) bendamustine (BEN) and a novel orally administered bendamustine agent (PO) that is utilizing the beneficial properties of superstaturated solid dispersions formulated in nanoparticles.
• Cracchiolo, M. J., Davis, L., Matiatos, A. P., Davini, D. W., Husnain, M., Simpson, R. J., Voudouris, V., & Katsanis, E. (2024). Comparable efficacy of oral bendamustine versus intravenous administration in treating hematologic malignancies. Cancer chemotherapy and pharmacology, 94(3), 361-372.
  More info

  The purpose of this study was to analyze potential differences in antitumor efficacy and pharmacokinetics between intravenous (IV) bendamustine and a novel orally administered (PO) bendamustine agent that is utilizing the beneficial properties of superstaturated solid dispersions formulated in nanoparticles.
• Davita, T. R., Giunto, N., Husnain, M., & Wong, K. (2024). A Case of Persistent Pasteurella multocida Cellulitis Complicated With Large Endocarditis Vegetation. Cureus, 16(9), e68825.
  More info

  In the realm of infective endocarditis, a distinct and infrequent player emerges - , an organism more commonly associated with zoonotic infections, now warranting careful consideration in this unique case report.   is a Gram-negative, facultative anaerobic cocco-bacillus and a common member of the oral bacterial flora of cats and dogs. In humans, it commonly causes skin and wound infections after bites and scratches. Disseminated   infection seeded into the heart valve is very rare and has only been reported in about one case per year worldwide with only 42 cases found in the literature and only five cases reported to have underlying liver cirrhosis as in our case. This is a case of a 73-year-old female with a past medical history of Child-Pugh B liver cirrhosis secondary to primary biliary cholangitis with portal hypertension, splenomegaly, pancytopenia, severe aortic stenosis, and paroxysmal atrial fibrillation presented to hospital with generalized weakness, fever, and new lower extremity rash 48 hours after last dose of antibiotic. She had recent hospitalization for left lower extremity cellulitis and bacteremia and received 14 days of high-dose oral amoxicillin-clavulanate with negative blood culture prior to discharge. She occasionally helps her son to feed his cats and dog whenever he travels. She was readmitted and a repeat blood culture showed . Transthoracic echocardiogram showed a 1.9 cm × 1 cm mobile mass attached to the anterior mitral valve leaflet, which was new compared to the prior study obtained during her first admission. She was not a suitable candidate for valve surgery due to her comorbidities.   was found to be susceptible to penicillin, ampicillin, levofloxacin with negative beta lactamase. Her cellulitis, fever, and bacteremia eventually resolved with intravenous antibiotics. She was ultimately discharged with a two-week course of intravenous ceftriaxone, continued with oral levofloxacin to complete six weeks of total treatment, and followed by long-term penicillin suppression. In this case report, we delve into a rare and intriguing clinical presentation of   endocarditis. Our patient is the second reported case which showed complication of native mitral valve endocarditis even in the setting of bacteremia resolution. This report sheds light on the challenging diagnosis and management of this uncommon yet clinically significant condition, highlighting the importance of vigilant and prompt intervention in cases of infective endocarditis with atypical causative agents.
• Hassan, D., Shakil Ur Rehman, S., Khalid, S., Tipu, I., & Husnain, M. (2024). Developing lifestyle intervention program for pre-hypertensive patients; consensus building using a modified Delphi approach. PloS one, 19(10), e0311766.
  More info

  Prehypertension is a preclinical state of hypertension which leads to an increased likelihood of coronary heart disease, myocardial infarction, cerebrovascular disease as well as target organ damage. Addressing pre-hypertension through early lifestyle interventions is crucial to mitigating these detrimental effects and improving long-term health outcomes. So, the main objective of this study is to develop a lifestyle intervention program (LSIP) for the management of prehypertension using consensus building approach.
• Kumar, J., Rehman, T., Barkat, R., Shah, B. L., Sindhu, L., Husnain, M., Siddiqui, M. J., & Hashmi, A. A. (2024). A Comparative Analysis of Clinical Features of Diabetes Mellitus Type 2 With Respect to Duration of Diabetes. Cureus, 16(11), e74849.
  More info

  Objectives Diabetes mellitus type 2 is a chronic metabolic disorder characterized by insulin resistance and progressive beta-cell dysfunction. As diabetes persists over time, more pronounced symptoms like polyuria, polydipsia, fatigue, and complications like neuropathy, retinopathy, and cardiovascular issues may develop. Therefore, this study assessed the clinical symptoms associated with type 2 diabetes regarding the duration of diabetes. Methodology This cross-sectional study was conducted in a secondary care hospital, using a non-probability convenient sampling method. Patients visiting the outpatient clinics were recruited in the study after obtaining informed written consent from them. The duration of the study was about six months from March 1, 2024, to August 31, 2024. A sample of 450 type 2 diabetic patients, aged 40-65 years, was included in this study. The study identified patients with type 2 diabetes by using their altered glycosylated hemoglobin (HbA1c) level recorded within the last 30 days, which reflects glycemic control. The demographic information, including age, gender, socioeconomic status, health condition, co-existing illnesses, and diabetes-related symptoms was also collected from the patients. SPSS software was used for data analysis. A chi-square and one-way analysis of variance (ANOVA) were employed to determine the association of clinical symptoms in type 2 diabetes mellitus. Results The study findings showed that the mean age was significantly higher in patients with diabetes for less than one year (60.44±15.88 years) compared to those with diabetes for one to five years (52.26±14.37 years) and more than five years (53.95±14.28 years) (p
• Raza, F. A., Monawwer, S. A., Husnain, M., Golubeva, D., Fatima, L., & Haque, M. A. (2024). A Comprehensive Case Report on Familial Multiple Lipomatosis. Clinical case reports, 12(12), e9664.
  More info

  Familial multiple lipomatosis (FML) is a rare autosomal dominant disorder characterized by the progressive development of encapsulated nodules predominantly on the trunk and extremities. Its genetic basis is linked to HMGA-2 gene over-expression. The condition is diagnosed via clinical history, ultrasound findings, and histological studies, and management mainly comprises surgical excision. This case report highlights the clinical characteristics, diagnostic challenges, and management of FML in a 38-year-old male.
• Barker, K., Koza, S., Katsanis, E., & Husnain, M. (2023). Hypophosphatemia and pre-infusion thrombocytopenia as biomarkers for CRS and ICANS after CAR T therapy. Bone marrow transplantation, 58(11), 1267-1269.
• Ghafoor, B., Masthan, S. S., Hameed, M., Akhtar, H. H., Khalid, A., Ghafoor, S., Allah, H. M., Arshad, M. M., Iqbal, I., Iftikhar, A., Husnain, M., & Anwer, F. (2023). Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects. Annals of hematology.
  More info

  Waldenström macroglobulinemia (WM) is a chronic B-cell lymphoproliferative disorder characterized by lymphoplasmacytic cell overgrowth in the bone marrow and increased secretion of IgM immunoglobulins into the serum. Patients with WM have a variety of clinical outcomes, including long-term survival but inevitable recurrence. Recent advances in disease knowledge, including molecular and genetic principles with the discovery of MYD88 and CXCR4 mutations, have rapidly increased patient-tolerable treatment options. WM patients may benefit from chemotherapy regimens that include rituximab-based regimens, alkylating drugs, proteasome inhibitors, monoclonal antibodies, and drugs targeting Bruton tyrosine kinase inhibitors. In light of these advancements, patients can now receive treatment customized to their specific clinical characteristics, focusing on enhancing the depth and durability of their response while limiting the adverse effects. Despite the rapidly developing therapeutic armament against WM, a lack of high-quality evidence from extensive phase 3 trials remains a significant challenge in the research. We believe clinical outcomes will keep improving when new medicines are introduced while preserving efficacy and minimizing toxicity.
• Mian, A., Naqvi, S. A., Ayaz, A., Husnain, M., Aljama, M. A., Mohyuddin, G. R., Koehn, K., Mohan, M., Bin Riaz, I., & Chakraborty, R. (2023). Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis. Leukemia research, 131, 107324.
  More info

  Anti-CD38 monoclonal antibodies (mAbs) are commonly used for treating newly diagnosed and relapsed/refractory (r/r) multiple myeloma (MM). However, concerns have been raised about the occurrence of second primary malignancies (SPMs) in patients receiving anti-CD38 mAbs. Assessing the safety data for rare adverse events like SPMs is challenging because individual clinical trials are typically focused on the primary endpoint. Therefore, we conducted a meta-analysis of randomized controlled trials (RCTs) published between January 2005 and April 2022, including patients with newly diagnosed or r/r MM. Our aim was to compare SPM rate with the use of anti-CD38 mAb-based regimens with other anti-myeloma regimens. After a median follow-up of 35.3 months (range: 8.2-56.2), we found that exposure to anti-CD38 mAbs was associated with an increased risk of developing SPMs compared to the control group (6.8% vs. 5.2%; Peto odds ratio [OR]: 1.53 [95% confidence interval (CI): 1.20-1.95]; I= 0%, p-value for heterogeneity= 0.44). This increased risk was primarily driven by non-melanoma cutaneous cancers (92 vs. 47; Peto OR: 1.77 [95% CI: 1.25-2.51]; I = 0%, p-value for heterogeneity = 0.54). However, there was no significant difference in the incidence of solid tumors (including malignant melanoma) (OR: 1.28 [95% CI: 0.85-1.95]) or hematologic SPMs (OR: 1.86; [95% CI: 0.81-4.27]). In conclusion, the use of anti-CD38 mAb-based combination regimens is associated with a higher risk of non-invasive cutaneous SPMs, but not solid tumors or hematologic SPMs. The increased occurrence of non-invasive cutaneous SPMs may be due to enhanced monitoring resulting from longer treatment duration with anti-CD38 mAbs.
• Wu, C., Manchen, P., Edelman, A., Husnain, M., Katsanis, E., Fuchs, D., Stephens, L., & Khurana, S. (2023). Refractory Pure Red Blood Cell Aplasia Secondary to Major ABO-Incompatible Allogeneic Stem Cell Transplantation Successfully Treated With Daratumumab. Journal of hematology, 12(6), 277-282.
  More info

  Pure red cell aplasia (PRCA) is a rare hematologic phenomenon that is usually associated with inherited genetic mutations such as in Diamond-Blackfan anemia. However, due to the emergence of allogenic stem cell transplantation in the treatment of various malignant and non-malignant disorders, the incidence of PRCA has increased. PRCA following hematopoietic stem cell transplant (HSCT) is more commonly seen in the setting of a major ABO-incompatible transplant. Treatment of allo-HSCT induced PRCA can be initially supportive as it takes time for the bone marrow to fully recover. However, prolonged and/or failure of the bone marrow to recover, significantly increases patient's risk of iron overload in the setting of frequent transfusions. Iron deposition can potentially lead to severe life-threatening multiorgan involvement which can be fatal. Therefore, earlier recognition and intervention with immunomodulators in patients who undergo frequent transfusions can be beneficial to mitigate this risk. Here, we present a case with severe transfusion-dependent PRCA following major ABO-incompatible allo-HSCT successfully treated with daratumumab.
• Chakraborty, R., Siddiqi, R., Willson, G., Gupta, S., Asghar, N., Husnain, M., Aljama, M. A., Behera, T. R., Anwer, F., Perrot, A., & Riaz, I. B. (2022). Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have high-risk cytogenetics: A meta-analysis of randomized controlled trials. Cancer, 128(12), 2288-2297.
  More info

  Despite routine evaluation of cytogenetics in myeloma, little is known regarding the impact of high-dose therapy (HDT) consolidation on overall survival (OS) or progression-free survival (PFS) in patients who have high-risk cytogenetics. The authors performed a meta-analysis of randomized controlled trials (RCTs) to assess the heterogeneity of HDT efficacy according to cytogenetic risk.
• Katsanis, E., Stea, B., Kovacs, K., Truscott, L., Husnain, M., Khurana, S., Roe, D. J., & Simpson, R. J. (2022). Feasibility and Efficacy of Partially Replacing Post-Transplantation Cyclophosphamide with Bendamustine in Pediatric and Young Adult Patients Undergoing Haploidentical Bone Marrow Transplantation. Transplantation and cellular therapy, 28(7), 390.e1-390.e10.
  More info

  Post-transplantation cyclophosphamide (PT-CY) is the most widely applied graft-versus-host disease (GVHD) prophylaxis regimen in T-cell replete haploidentical bone marrow transplantation (haplo-BMT). Although PT-CY has met with great success in the haplo-BMT arena by suppressing GVHD, patients without acute GVHD have high relapse rates. One strategy to reduce relapse rates being explored by others is a dosage reduction of PT-CY. We have taken a different approach in evaluating whether partially replacing PT-CY with post-transplantation bendamustine (PT-BEN) would be advantageous, an idea based on our preclinical research identifying several beneficial immunomodulatory properties of BEN. We therefore initiated and completed a Phase Ia trial to evaluate the progressive substitution of PT-CY with PT-BEN (ClinicalTrials.gov identifier NCT02996773). We compared outcomes between 13 patients with high-risk hematologic malignancies who received PT-CY/BEN and 31 contemporaneous haplo-BMT recipients treated with the same myeloablative conditioning regimens but receiving only PT-CY. We found that partial replacement of PT-CY with PT-BEN (PT-CY/BEN) on day +4 was well tolerated and associated with significantly earlier trilineage engraftment. We also report favorable trends toward significant improvements on univariate and multivariate analyses with PT-CY/BEN compared with PT-CY with respect to rates of chronic GVHD (hazard ratio [HR], .08; 95% confidence interval [CI], .005 to 1.11; P = .06), and GVHD-free relapse-free survival (GRFS) (HR, .22; 95% CI, .05 to .86; P = .039). Our human trial has now transitioned to Phase Ib, which will further evaluate the safety and potential benefits of PT-CY/BEN. Herein we also expand our pediatric, adolescent, and young adult experience to 31 patients, demonstrating overall survival, progression-free survival, and GRFS at 3 years of 85.6%, 76.1%, and 58.2%, respectively, in a largely racial/ethnic minority cohort. PT-CY/BEN appears to be a promising treatment option that requires further evaluation.
• Hashmi, H., Husnain, M., Khan, A., & Usmani, S. Z. (2021). CD38-Directed Therapies for Management of Multiple Myeloma. ImmunoTargets and therapy, 10, 201-211.
  More info

  The survival outcomes for multiple myeloma have improved several-fold in the past two decades, primarily due to the introduction of therapies with novel mechanisms of action including immunomodulatory agents, proteasome inhibitors, stem cell transplant and monoclonal antibodies in the schema of therapy. Antibody-based therapies targeting the surface marker CD38, namely daratumumab and isatuximab, have emerged as being highly effective as single agents as well as in combination regimens for both newly diagnosed and relapsed settings. Herein, the authors summarize the most recent data with both the current and emerging CD38-directed therapies in multiple myeloma.
• Riaz, I. B., He, H., Ryu, A. J., Siddiqi, R., Naqvi, S. A., Yao, Y., Husnain, M., Narasimhulu, D. M., Mathew, J., Sipra, Q. U., Vandvik, P. O., Joseph, R. W., Liu, H., Wang, Z., Herasevich, V., Singh, P., Hussain, S. A., Ho, T. H., Bryce, A. H., , Pagliaro, L. C., et al. (2021). A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma. European urology, 80(6), 712-723.
  More info

  Identifying the most effective first-line treatment for metastatic renal cell carcinoma (mRCC) is challenging as rapidly evolving data quickly outdate the existing body of evidence, and current approaches to presenting the evidence in user-friendly formats are fraught with limitations.

Poster Presentations

• Husnain, M. (2021, December). Non-Relapse Mortality in TP53-Mutated MDS/AML - a Multi-Center Collaborative Study. American Society of Hematology. Atlanta, GA.

Reviews

• Filioglou, D., Husnain, M., Khurana, S., Simpson, R. J., & Katsanis, E. (2023. Has the shortage of fludarabine altered the current paradigm of lymphodepletion in favor of bendamustine?(p. 1329850).
  More info

  The most common lymphodepletion regimen used prior to infusion of chimeric antigen receptor-T cells (CAR-T) is cyclophosphamide (CY) in combination with fludarabine (Flu) (CY-FLU). While cyclophosphamide (CY) possesses lymphotoxic effects, it concurrently preserves regulatory T cell activity, potentially affecting the efficacy of CAR-T cells. Moreover, the use of fludarabine (FLU) has been linked to neurotoxicity, which could complicate the early detection of immune effector cell-associated neurotoxicity syndrome (ICANS) observed in CAR-T cell therapy. Given the ongoing shortage of FLU, alternative lymphodepleting agents have become necessary. To date, only a limited number of studies have directly compared different lymphodepleting regimens, and most of these comparisons have been retrospective in nature. Herein, we review the current literature on lymphodepletion preceding CAR-T cell therapies for lymphoid hematologic malignancies, with a specific focus on the use of bendamustine (BEN). Recent evidence suggests that administering BEN before CAR-T cell infusion yields comparable efficacy, possibly with a more favorable toxicity profile when compared to CY-FLU. This warrants further investigation through randomized prospective studies.